This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Incyte Corp. (INCY) rallied 1.79% to $100.32 Monday, on what proved to be an all-around great trading session for the stock market, with the S&amp;P 500 Index rising 0.19% to 7,412.84 and the Dow Jones Industrial Average rising 0.19% to 49,704.47.
This was the stock's second consecutive day of gains.
Incyte Corp. closed 10.66% short of its 52-week high of $112.29, which the company achieved on January 7th.
The stock outperformed some of its competitors Monday, as Alnylam Pharmaceuticals Inc. (ALNY) fell 3.46% to $284.84, Bio-Techne Corp. (TECH) fell 1.94% to $47.42, and BioMarin Pharmaceutical Inc. (BMRN) fell 2.74% to $52.58.
Trading volume (1.7 M) eclipsed its 50-day average volume of 1.5 M.
Data source: Dow Jones Market Data, FactSet. Data compiled May 11, 2026.
This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-11-26 1708ET

INCY

Incyte Corp. (INCY) shares rose 1.79% to $100.32 on a strong trading day, outperforming competitors like Alnylam Pharmaceuticals, Bio-Techne, and BioMarin, which saw declines. The S&P 500 and Dow Jones both increased by 0.19%. Incyte's stock is currently 10.66% below its 52-week high of $112.29 reached on January 7th, with trading volume at 1.7 million, surpassing its 50-day average of 1.5 million.

MarketWatch Automated

Incyte

VanEck Biotech ETF

VG Health

Proshares Ultra Nasdaq Biotech

iShares US Pharma

SPDR S&P Biotech

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

S&P 500

Dow Jones Industrial Average

Alnylam Pharma

Bio-Techne

BioMarin Pharma

Factset Research

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day